Topic

Hypertension

Antihypertensive drug access, resistant hypertension, aldosterone synthase inhibitors, cardiovascular formulary positioning, and payer coverage for blood-pressure therapies.

3 articles·Lives underPricing & Access Evidence·Last updated 2026-07-07

Evidence· July 7, 2026 · 21 min read

Calcium Channel Blocker Adverse Events in FAERS: 619,000 Reports and Class-Wide Signals

By Ran Chen#Hypertension #Cardiovascular #Real-World Evidence

Evidence· July 1, 2026 · 17 min read

ACE Inhibitors and ARBs in FAERS: 46,000 Reports in 2025 and the Core Signals

By Ran Chen#Hypertension #Cardiovascular #Real-World Evidence

Approvals· May 28, 2026 · 7 min read

Baxfendy coverage guide: baxdrostat access for uncontrolled hypertension

By Ran Chen#Hypertension #Cardiovascular #FDA Approval